This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum - Takeaway - MDSpire
Clinical Guidelines
Feature

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min

Share

  • 1

    Daraxonrasib nearly doubles overall survival in metastatic pancreatic cancer.

  • 2

    Patients treated lived a median of 13.2 months vs 6.7 months on standard treatment.

  • 3

    GSK's Mo-Rez shows significant tumor responses in resistant gynecologic cancers.

  • 4

    Gilead acquires Tubulis for $3.15B to expand ADC capabilities.

  • 5

    FDA now publishes complete response letters in real time.

  • 6

    Biocon launched two interchangeable biosimilars for osteoporosis.

  • 7

    Increased focus on antibody discovery through AI technologies.

Original Source(s)

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

  • April 21, 2026

Related Content

Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min
This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...